Table 5.
EGFRvIII | Best Response | ||
---|---|---|---|
Progressive Disease | Disease Control (Partial Response or Stable Disease) | ||
EGFRvIII absent by ΔΔCt | 12 (67%) | 6 (33%) | P = 0.0099 |
EGFRvIII present by ΔΔCt | 5 (25%) | 15 (75%) | (Chi-square) |
EGFRvIII mean fold change | 10.62 | 63.76 | P = 0.04 |
EGFRvIII median fold change | 3.16 | 11.11 | (Wilcoxon) |
Erlotinib treated patients | |||
EGFRvIII absent by ΔΔCt | 6 (55%) | 5 (45%) | P = 0.21 |
EGFRvIII present by ΔΔCt | 3 (33%) | 10 (77%) | (Fisher's) |
Non-erlotinib treated patients | |||
EGFRvIII absent by ΔΔCt | 6 (86%) | 1 (14%) | P = 0.21 |
EGFRvIII present by ΔΔCt | 2 (29%) | 5 (71%) | (Fisher's) |